PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|April 23, 2014
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-05-07-2014
- Volume 10
- Issue 5
Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement
Author(s)Melanie Sena
Bristol-Myers Squibb and Samsung BioLogics expand their manufacturing agreement to cover biologic medicines.
Advertisement
Bristol-Myers Squibb and Samsung announced their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance.
Source:
Articles in this issue
over 12 years ago
Using eClinical Systems for Supply-Chain Managementover 12 years ago
FDA and Industry Take Action for a More Secure Drug Supply Chainover 12 years ago
Packaging Becomes Enabler for Biopharmaceuticalsover 12 years ago
Azzur Group and BioSPEQ Announce Mergerover 12 years ago
Eli Lilly Launches Second Education Program for Medical Studentsover 12 years ago
Global Instability Impacts Brazil's Pharma Marketover 12 years ago
US Biopharma Worries About Losing Lead in Innovationover 12 years ago
Outsourcing Remains Strong In Traditional AreasAdvertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement